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Abstract: Abstract 
The purpose of this study was to evaluate 3-year clinical outcomes following percutaneous coronary 
intervention with sirolimus-eluting stents (SES) in insulin-treated diabetic (DM-insulin) patients and 
non-insulin-treated diabetic (DM-non-insulin) patients compared with non-diabetic (non-DM) 
patients. Among 10778 consecutive patients treated exclusively with SES in the j-Cypher registry, we 
identified 996 DM-insulin patients, 3404 DM-non-insulin patients, and 6378 non-DM patients. As 
compared with the non-DM group, the adjusted risk for serious cardiovascular event (composite of all-
cause death, myocardial infarction, and stroke) was significantly higher in the DM-insulin group 
(hazard ratio (HR): 1.12, 95% confidence interval (CI): 1.03 to 1.23; p=0.01), but not in the DM-non-
insulin group (HR: 1.02, 95% CI: 00.96 to 1.09; p=0.47). The adjusted risk for target lesion 
revascularization (TLR) was significantly higher both in the DM-insulin group (odds ratio (OR): 1.52, 
95% CI: 1.19 to 1.92; p=0.0006), and in the DM-non-insulin group (OR: 1.24, 95% CI: 1.05 to 1.45; 
p=0.009). In conclusion, there was diabetes-associated excess risk of TLR regardless of insulin use in 
this large, real world study in Japanese patients with SES implantation. However, regarding serious 
cardiovascular events, an excess risk was seen only in the DM-insulin group. The risk for serious 
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The purpose of this study was to evaluate 3-year clinical outcomes following percutaneous coronary intervention 
with sirolimus-eluting stents (SES) in insulin-treated diabetic (DM-insulin) patients and non-insulin-treated 
diabetic (DM-non-insulin) patients compared with non-diabetic (non-DM) patients. Among 10778 consecutive 
patients treated exclusively with SES in the j-Cypher registry, we identified 996 DM-insulin patients, 3404 
DM-non-insulin patients, and 6378 non-DM patients. As compared with the non-DM group, the adjusted risk for 
serious cardiovascular event (composite of all-cause death, myocardial infarction, and stroke) was significantly 
higher in the DM-insulin group (hazard ratio (HR): 1.12, 95% confidence interval (CI): 1.03 to 1.23; p=0.01), 
but not in the DM-non-insulin group (HR: 1.02, 95% CI: 00.96 to 1.09; p=0.47). The adjusted risk for target 
lesion revascularization (TLR) was significantly higher both in the DM-insulin group (odds ratio (OR): 1.52, 
95% CI: 1.19 to 1.92; p=0.0006), and in the DM-non-insulin group (OR: 1.24, 95% CI: 1.05 to 1.45; p=0.009). 
In conclusion, there was diabetes-associated excess risk of TLR regardless of insulin use in this large, real world 
study in Japanese patients with SES implantation. However, regarding serious cardiovascular events, an excess 
risk was seen only in the DM-insulin group. The risk for serious cardiovascular events was similar between 
DM-non-insulin and non-DM patients. 







The present study evaluates the impact of insulin-treated and non-insulin-treated diabetes mellitus 
(DM) on the incidences of serious cardiovascular events and repeated coronary revascularization following 
sirolimus-eluting stent (SES) implantation. We evaluated 3-year clinical outcomes of both insulin-treated and 
non-insulin-treated diabetic patients relative to non-diabetic patients in a large cohort of patients who underwent 
percutaneous coronary intervention (PCI) using SES in the real world clinical practice in Japan. 
Methods 
The design and patient enrollment of the j-Cypher registry has been published previously(1). In brief, 
the j-Cypher registry is a physician-initiated prospective, multicenter prospective cohort study in Japan enrolling 
consecutive patients who underwent SES implantation at 37 centers in Japan (Supplemental Appendix A). 
Institutional review boards at all 37 participating centers approved this study. Written informed consent was 
obtained from all patients.  
After SES implantation, dual antiplatelet treatment with aspirin plus thienopyridine derivative 
(ticlopidine 200 mg/day or clopidogrel 75mg/day) was to be maintained for at least 3 months. Thereafter, the 
decision regarding the duration of dual antiplatelet therapy was left to the discretion of each attending physician. 
Life-long use of aspirin was recommended after the procedure.  
Although data entry was basically left to the individual sites, the clinical research coordinators 
(Supplemental Appendix B) in the data management center (Kyoto University Hospital, Department of 
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Cardiology) supported data entry when necessary. Logical inconsistencies were resolved by inquiries to the site 
investigators and/or by audits against the original data sources. Follow-up data were obtained from hospital 
charts or by contacting patients or referring physicians at 30 days, 6 months, and 1 year after the procedure, and 
yearly thereafter. When death, myocardial infarction, and stent thrombosis were reported, the events were 
adjudicated using the original source documents by a clinical events committee (Supplemental Appendix C). 
Adjudication of target lesion revascularization (TLR) events was left to the judgment of the local investigators.  
Between August 2004 and November 2006, 12824 patients (19675 lesions) were enrolled in the 
j-Cypher registry, and 10778 patients (14811 lesions) who were treated exclusively with sirolimus-eluting stent 
(SES) constituted the study population for the present analysis. There were 4400 diabetic patients and 6378 
non-diabetic patients (non-DM). The diabetic patients were stratified to 3404 patients without insulin therapy 
(DM-non-insulin) and 996 patients treated with insulin (DM-insulin) (Figure 1). Among 3404 DM-non-insulin 
patients, 2330 patients were treated with oral glucose-lowering drugs and remaining 1074 patients were managed 
without pharmacologic treatment. In this post-hoc subanalysis of the j-Cypher registry, baseline characteristics, 
and clinical outcomes in the DM-insulin group and in the DM-non-insulin group were compared with those in 
the non-DM group. The primary outcome measure for the current analysis was serious cardiac events (a 
composite of all-cause death, myocardial infarction and stroke) assessed at 3 years after SES implantation. The 
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secondary outcome measure included the individual components of the primary outcome events, definite stent 
thrombosis, target lesion revascularization (TLR), non-TLR, and any coronary revascularization.  
Diabetes mellitus was defined as fasting plasma glucose level ≥ 126 mg/dl, glucose level 
>200mg/dl 2 hour after 75g oral glucose tolerance test, casual plasma glucose level >200mg/dl or use of 
anti-diabetic medications. Diagnosis of diabetes and use of insulin at the time of the index sirolimus-eluting stent  
(SES) implantation were reported by the site investigators. 
Death was regarded as cardiac in origin unless obvious non-cardiac causes could be identified. Any 
death during the index hospitalization was regarded as cardiac death. Sudden death was defined as unexplained 
death in previously stable patients. Myocardial infarction was adjudicated according to the definition in the 
Arterial Revascularization Therapy Study(2). Within 1 week of index procedure, only Q-wave myocardial 
infarction was adjudicated as myocardial infarction. TLR was defined as either percutaneous coronary 
intervention (PCI) or coronary artery bypass grafting (CABG) due to restenosis or thrombosis of the target lesion, 
including the proximal and distal edge segments as well as the ostium of the side-branches. Non-TLR was 
defined as coronary revascularization procedures, either PCI or CABG, other than TLR. Stent thrombosis was 
defined according to Academic Research Consortium definition(3). Unless otherwise noted, definite stent 
thrombosis assessed on a patient-level basis was used as the endpoint for stent thrombosis.  
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Continuous variables are presented with mean ± standard deviation, and categorical variables are 
expressed as number and percentages. Categorical variables were compared with the Chi-square test. Continuous 
variables were compared with the t test or Wilcoxon rank-sum test based on the distribution. Incidences of the 
primary and secondary outcome measures were estimated by the Kaplan-Meier method and differences were 
assessed with the log-rank test.  
Adjusted risks of DM-insulin versus non-DM and DM-non-insulin compared to non-DM for the 
primary outcome measure were estimated by multivariable Cox proportional hazard model by incorporating 
variable DM-insulin or DM-non-insulin into multivariable models with 23 risk-adjustment variables listed in 
supplemental table 1 and 2. Continuous risk-adjustment variables were dichotomized according to the clinically 
meaningful reference values. The results were expressed as adjusted hazard ratios and their 95% confidence 
intervals. For the evaluation of adjusted risk for target lesion revascularization (TLR), a multivariable logistic 
regression model instead of Cox proportional hazard model was used, because restenosis has been well known to 
be a time-related phenomenon and also the timing of TLR could be highly influenced by physicians’ and 
patients’ decision. By using logistic regression model, we could minimize the influence of the timing of TLR on 
the adjusted analysis for TLR(4). Patients included in the multivariable logistic regression model were 1882 
patients with TLR within 3 years and 2415 patients who completed 3-year follow-up without TLR. Same 
independent variables used in the Cox proportional hazard model were incorporated in the multivariable logistic 
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regression model. The results were expressed as adjusted odds ratio and their 95% confidence intervals. All 
analyses were conducted using JMP Version 7.1 (SAS Institute Inc., Cary, North Carolina). All reported 
p-values were 2-sided and p-values less than 0.05 were considered significant. 
Results 
As compared with non-DM patients, both DM-insulin and DM-non-insulin patients were younger, 
had higher body mass index, and more often had hypertension, end-stage renal disease including hemodialysis, 
heart failure, prior stroke, multi-vessel disease, and prior coronary revascularization procedures. Furthermore, 
DM-insulin patients were more often women, more often had peripheral vascular disease, and less often had 
smoking habit and acute coronary syndrome as compared with non-DM patients (Table 1). 
 Both DM-insulin and DM-non-insulin patients, as compared with non-DM patients, had more 
complex lesion and procedural characteristics such as long lesions, small vessel size, severe calcification, longer 
total stent length and higher final inflation pressure.  
Cumulative incidences of clinical events through 3 years are listed in Table 2. Crude incidence of 
serious cardiovascular events (all-cause death, myocardial infarction and stroke) was significantly higher in the 
DM-insulin group than that in the non-DM group. However, although the cumulative incidence of serious 
cardiovascular events in the DM-non-insulin group tended to be higher than that in the non-DM group, the 
difference did not reach statistical significance (Figure 2). After adjusting the confounders with multivariable 
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Cox proportional hazard model, the risk of DM-insulin versus non-DM for serious cardiovascular events 
remained significant (hazard ratio: 1.12, 95% confidence intervals: 1.03 to 1.23; p = 0.01). However, after 
adjusting confounders, there was no more a trend for the excess risk of DM-non-insulin versus non-DM for 
serious cardiovascular events (hazard ratio 1.02, 95% confidence intervals: 0.96 to 1.09; p = 0.47) (Supplemental 
table 1).  
Crude incidence of all-cause death was markedly higher in the DM-insulin-group and significantly 
higher in the DM-non-insulin group than that in the non-DM group. The incidence of stroke was significantly 
higher in the DM-insulin group than that in the non-DM group, while the incidence of stroke was not different 
between the DM-non-insulin group and the non-DM group. The incidences of myocardial infarction and stent 
thrombosis were not different among the 3 groups (Table 2 and Figure 3).  
Crude incidences of target lesion revascularization (TLR) in the DM-insulin-group and in the 
DM-non-insulin group were significantly higher than that in the non-DM group (Figure 4(A)). After adjusting 
confounders by multivariable logistic regression analysis, the risks of both DM-insulin versus non-DM and 
DM-non-insulin versus non-DM for TLR remained significant (odds ratio: 1.52, 95% confidence intervals: 1.19 
to 1.92; p = 0.0006, and odds ratio: 1.24, 95% confidence intervals: 1.05 to 1.45; p= 0.009, respectively) 
(Supplemental table 2). 
 9 
Crude incidences of non-target lesion revascularization (TLR) and any coronary revascularization in 
the DM-insulin-group and in the DM-non-insulin group were also significantly higher than that in the non-DM 
group (Table 2 and Figure 4(B)).   
 
Discussion 
The major findings of the current analysis are as follows: (1) Insulin-treated diabetic patients as 
compared with non-diabetic patients had significantly higher adjusted risk for the serious cardiovascular events 
such as death, myocardial infarction, and stroke during 3 years after sirolimus-eluting stent (SES) implantation; 
(2) The risk of non-insulin-treated diabetic patients for the serious cardiovascular events was not different from 
the risk of non-diabetic patients; and (3) Both insulin-treated and non-insulin-treated diabetic patients had 
significantly higher risk for TLR than non-diabetic patients. 
Although insulin-treated diabetic patients has been known to be associated with worse outcome as 
compared with non-insulin-treated diabetic patients, the risk of non-insulin-treated diabetic patients relative to 
non-diabetic patients for adverse cardiovascular events after percutaneous coronary intervention (PCI) has not 
been adequately evaluated and there is only a few studies including small number of diabetic patients(5-7). In the 
current analysis encompassing large number of diabetic patients, both insulin-treated and non-insulin-treated 
diabetic patients had more co-morbidities such as renal failure, stroke, and heart failure than non-diabetic 
 10 
patients. Also, triple vessel disease was more prevalent in both insulin-treated and non-insulin-treated diabetic 
patients than in non-diabetic patients. Insulin-treated diabetic patients had significantly higher risk for serious 
cardiovascular events, even after adjusting these confounding factors. However, the risk for serious 
cardiovascular events was similar between non-insulin-treated diabetic patients and non-diabetic patients. It was 
noteworthy that there were absolutely no differences in the incidences of myocardial infarction and stroke 
between non-insulin-treated diabetic patients and non-diabetic patients (Figure 3(B)(C)). This finding seemed to 
be in contradiction to the observations suggesting that non-insulin-treated diabetic patients without known 
cardiovascular disease had higher risk for future cardiovascular events than non-diabetic patients(8). Patients 
with cardiovascular disease without a previous diagnosis of diabetes were reported to have very high (60-66%) 
prevalence of diabetes or impaired glucose tolerance when oral glucose tolerance test was conducted(8, 9). The 
potential differences in the incidences of serious cardiovascular events between non-insulin-treated diabetic 
patients and non-diabetic patients might have been diluted by the presence of patients with undiagnosed diabetes 
or impaired glucose tolerance in patients included in the non-diabetic group. Additionally, the good prognosis of 
non-insulin-treated diabetic patients in the current study might reflect the generally low cardiovascular event 
rates among Japanese diabetic patients. Lesser degree of hyperinsulinemia and insulin resistance of Japanese 
diabetic patients as compared with diabetic patients in United States and Europe might be related to low 
cardiovascular event rates among Japanese diabetic patients(10-12). 
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 The observation that the risk for serious cardiovascular events was similar between 
non-insulin-treated diabetic patients and non-diabetic patients might have some clinical implication in selecting 
coronary revascularization strategy in diabetic patients. Although a meta-analysis of randomized controlled trials 
comparing coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) before 
drug-eluting stent era suggested higher mortality in the PCI group in diabetic patients, non-insulin-treated and 
insulin-treated diabetic patients were not discriminated in any of these trials(13). Considering the equivalent 
clinical outcome in terms of serious cardiovascular events between non-insulin-treated diabetic patients and 
non-diabetic patients, it might be important to discriminate non-insulin-treated and insulin-treated diabetic 
patients in the comparison between PCI and CABG. 
 Although insulin-treated diabetic patients had worse outcome even after adjusting co-morbidities in the 
current study, relationship between insulin use and vascular events is debatable. Previous epidemiological 
studies demonstrated the increased cardiovascular risk with higher serum insulin levels(14-16). This might 
suggest that insulin use was causally related to the higher rate of cardiovascular events. On the other hand, the 
Diabetes Control and Complications Trial and the subsequent Epidemiology of Diabetes Interventions and 
Complications (DCCT-EDIC) illustrated that intensive insulin therapy in type 1 diabetic patients reduced the risk 
of any cardiovascular disease by 42% and the risk of non-fatal myocardial infarction, stroke, or cardiovascular 
death by 57%(17). Patients with insulin producing neoplasm do not have an increase in clinically overt 
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atherosclerotic disease(18). Because insulin has both proatherogenic and antiatherogenic properties, insulin 
therapy may differentially modify risk of cardiovascular events depending on the presence of insulin resistance 
and hyperinsulinemia(19, 20).  
 Regarding target lesion revascularization (TLR) after sirolimus-eluting stent  
(SES) implantation, both insulin-treated diabetic and non-insulin-treated patients had significantly higher risk 
than non-diabetic patients. Diabetic patients are known to have smaller vessel size, longer lesion length, greater 
atherosclerotic burden and heavier calcification as compared with non-diabetic patients. Although these 
anatomic characteristics of diabetic patients predispose to restenosis, the higher risk of insulin-treated and 
non-insulin-treated diabetic patients relative to non-diabetic patients for TLR remained highly significant even 
after adjusting anatomical confounders such as multi-vessel disease, reference diameter, and total stent length. 
This finding might suggest that insulin resistance and resultant hyperinsulinemia played an important role in 
augmenting neo-intimal proliferation after SES implantation.  Indeed, insulin stimulates vascular smooth 
muscle cell proliferation both directly and by enhancing the effects of other mitogens(21). Although drug-eluting 
stents reduced restenosis rate and TLR rate in diabetic patients in the same magnitude as in non-diabetic patients, 
absolute rates of restenosis and TLR in diabetic patients, particularly in insulin-treated diabetic patients, still 
remained far from satisfactory, highlighting the need for development of drug-eluting stent with more potent 
anti-restenosis efficacy. 
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 Both insulin-treated and non-insulin-treated diabetic patients also had significantly higher risk for non- 
target lesion revascularization (TLR) than non-diabetic patients, suggesting more aggressive atherosclerotic 
progression in the coronary artery territories other than the target stented-area in diabetic patients. It is intriguing 
why this more aggressive atherosclerotic progression did not lead to higher incidence of serious cardiovascular 
events in non-insulin-treated diabetic patients relative to non-diabetic patients. 
 Although diabetes has been shown to be an independent predictor of stent thrombosis in patients 
treated with drug-eluting stent in the previous studies(3, 22, 23), the rates of stent thrombosis were very low in 
all 3 groups in our study and we did not observe increased risk of stent thrombosis in insulin-treated and 
non-insulin-treated diabetic patients. However, owing to the small number of stent thrombosis events, this 
finding should be interpreted with caution.     
 There were several important limitations to interpret the results of this study. First, we did not have 
detailed information on the status of diabetes. The proportion of patients with type 1 and type 2 diabetes was not 
recorded, nor were the glycosylated hemoglobin values. Second, although we made extensive statistical 
adjustment, there might still be unmeasured confounding factors. Third, we could not discriminate between 
clinically-driven and angiography-driven TLR. Japanese practice of routine follow-up angiography after 
percutaneous coronary intervention (PCI) might have exaggerated the differences in TLR among insulin-treated 
diabetic patients, non-insulin-treated diabetic patients, and non-diabetic patients. 
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Table 1. Baseline Characteristics 
  non-DM  DM-non-insulin  p value* DM-insulin  p value*  
Characteristics           
No. of patients 6378 3404   996   
Age (years)  68.8 ± 10.6 67.9 ± 9.4 <0.0001 66.7 ± 9.4 <0.0001 
Age > 80 years  952, (15%) 347, (10%) <0.0001 63, (6%) <0.0001 
Men  4867, (76%) 2585, (76%) 0.68 671, (67%) <0.0001 
Body mass Index (%)  23.7 ± 4.0 24.3 ± 3.7 <0.0001 24.1 ± 3.4 0.0007 
Hypertension   4670, (73%) 2638, (78%) <0.0001 761, (76%) 0.03 
Current smoking  1265, (20%) 696, (21%) 0.47 158, (16%) 0.003 
eGFR < 30ml /min/1.73m2           
    without hemodialysis 229, (3.7%) 192, (6.0%) <0.0001 101, (12%) <0.0001 
    with hemodialysis  238, (3.7%) 191, (5.6%)  <0.0001 165, (17%) <0.0001 
Peripheral vascular disease  697, (11%) 409, (12%)  0.11 170, (17%) <0.0001 
Prior myocardial infarction 1713, (27%) 1026, (30%) 0.0006 285, (29%) 0.25 
Prior stroke  523, (8.2%) 354, (10%) 0.0003 130, (13%) <0.0001 
Prior PCI  2962, (46%) 1704, (50%) 0.0006 513, (52%) 0.003 
Prior coronary artery bypass grafting  401, (6.3%) 274, (8.1%)  0.001 112, (11%) <0.0001 
Heart failure  718, (11%) 511, (15%) <0.0001 231, (23%) <0.0001 
Acute coronary syndrome  1403, (25%) 734, (22%) 0.62 171, (17%) 0.0004 
    STEMI  455, (7.1%) 225, (6.6%) 0.33 53, (5.3%) 0.03 
Multivessel disease  2911, (46%) 1884, (55%) <0.0001 597, (60%) <0.0001 
    Triple-vessel disease  594, (9.3%) 498, (15%) <0.0001 164, (17%) <0.0001 
    Unprotected Left main  356, (5.6%) 206, (6.1%) 0.34 73, (7.3%) 0.03 
No. of lesions treated   1.34 ± 0.63 1.40 ± 0.68 <0.0001 1.47 ± 0.76 <0.0001 
Total No. of stents  1.69 ± 0.98 1.81 ± 1.06 <0.0001 1.95 ± 1.21 <0.0001 
Total length of stents, (mm)  37.3 ± 24.3 40.5 ± 26.4 <0.0001 43.9 ± 29.6 <0.0001 
Treatment of DM           
   Oral hypoglycemic agent  - 2330, (69 %)  92, (9%)   
   Insulin dependent DM  - -  996, (100%)   
Baseline medications      
Table(s)
Cilostazol 207, (3.3%) 100, (3.0%) 0.43 44, (4.5%) 0.07 
Statins 3057, (48%) 1687, (50%) 0.08 474, (48%) 0.87 
ACE inhibitors 965, (15%) 597, (18%) 0.002 169, (17%) 0.14 
ARBs 2283, (36%) 1336, (40%) 0.0004 407, (41%) 0.002 
Beta blockers 1692, (27%) 1012, (30%) 0.0004 304, (31%) 0.009 
Lesion Characteristics        
No. of lesions                                                                  8574 4774   1463   
Target Lesion location      <0.0001    <0.0001  
    Left anterior descending  3673, (43%) 1944, (41%)  521, (36%)  
    Left circumflex 1801, (21%) 1010, (21%)  319, (22%)  
    Right 2758, (32%) 1610, (34%)  545, (37%)  
    Left main 278, (3.2%) 160, (3.4%)  61, (4.2%)  
    Saphenous vein graft 51, (0.6%) 43, (0.9%)  15, (1.0%)  
Lesion length >= 30mm  1135, (13%) 741, (16%) 0.0004 270, (19%) 0.0001 
Reference diameter < 2.5mm  2268, (27%) 1438, (30%) <0.0001  490, (34%) <0.0001  
In-stent restenosis  1074, (13%) 625, (13%) 0.36 196, (13%) 0.36 
Chronic total occlusion  734, (8.6%) 478, (10%) 0.006 136, (9.3%) 0.36 
Severe calcium  656, (7.7%) 454, (9.5%) 0.0002 201, (14%) 0.0001 
Bifurcation lesion  1743, (20%) 848, (18%) 0.0003 266, (18%) 0.054 
Total stent length per lesion (mm)  28.1 ± 14.8  29.2 ± 15.8  <0.0001  30.3 ± 16.5 0.0001 
Minimal stent size (mm)  2.91 ± 0.37 2.87 ± 0.37 <0.0001  2.83 ± 0.36 0.0001 
Post dilatation  3755, (44%) 2048, (43%) 0.29 688, (48%) 0.01 
Maximum inflation pressure (atm)  17.9 ± 4.4 18.3 ± 4.2 0.006 18.6 ± 4.4 0.0004 
All data are number unless otherwise indicated. Continuous variables were expressed as mean 
value ± standard deviation. * p value : vs. non-DM. 
ACE inhibitors = angiotensin-converting enzyme inhibitors, ARBs = angiotensin receptor 
blockers, CABG = coronary artery bypass grafting, DM = diabetes mellitus, eGFR = estimated 
glomerular filtration rate, PCI = percutaneous coronary intervention and STEMI= ST-segment 
elevation myocardial infarction. 
 
Table 2. Clinical Event Rates Through 3 years 
  non-DM  DM-non-insulin DM-insulin 
 n = 6378 n = 3404 p value* n = 996 p value* 
Death/MI/Stroke 649, (12.7%) 392, (13.8%) 0.057 185, (22.3%) <0.0001 
All-cause Death 412, (8.2%) 267, (9.3 %) 0.01 132, (16.2%)  <0.0001 
   Cardiac Death 203, (3.8%) 135, (4.6%) 0.046 62, (8.1%) <0.0001 
   associated with Heart Failure 58, (1.1%) 44, (1.5%) 0.08 19, (2.7%) 0.003 
   associated with Myocardial Infarction 17, (0.3%) 19, (0.7%) 0.02 6, (0.6%) 0.07 
   Sudden Death 76, (1.5%) 39, (1.4%) 0.85 25, (3.5%) 0.0007 
 Myocardial infarction 124, (2.7%) 61, (2.5%) 0.57 26, (2.9%) 0.14 
Stroke  193, (3.7%) 110, (4.0%) 0.57 51, (6.6%) <0.0001 
Stent Thrombosis:              definite  57, (1.2%) 32, (1.2 %) 0.84 12, (1.3%) 0.33 
definite/probable 65, (1.4%) 38, (1.4%) 0.67 13, (1.4%) 0.39 
definite/probable/possible  153, (3.1%) 84, (3.1%) 0.84 41, (5.1%) 0.001 
Target lesion revascularization 535, (10.2%)  394, (13.8%) <0.0001 168, (19.3%) <0.0001 
Coronary artery bypass graft 85, (1.8%) 57, (2.0%) 0.17 19, (2.4%) 0.13 
Non-target lesion revascularization 1199, (22.1%) 815, (28.1%) <0.0001 274, (32.8%) <0.0001 
Any Revascularization  1481, (27.2%)  999, (34.0%) <0.0001 346, (40.1%) <0.0001 
 All data are number unless otherwise indicated. * p value : vs. non-DM 
DM = diabetes mellitus, MI = myocardial infarction, 
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